BIOMAT Database Logo BIOMAT Database Logo

[Towards systematic screening for mucoviscidosis?]. 1993

G Pescia, and G Van Melle, and F Thonney, and C Auer, and D Schorderet, and S Fokstuen
Division autonome de génétique médicale, CHUV, Lausanne.

UI MeSH Term Description Entries
D008297 Male Males
D008565 Membrane Proteins Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors. Cell Membrane Protein,Cell Membrane Proteins,Cell Surface Protein,Cell Surface Proteins,Integral Membrane Proteins,Membrane-Associated Protein,Surface Protein,Surface Proteins,Integral Membrane Protein,Membrane Protein,Membrane-Associated Proteins,Membrane Associated Protein,Membrane Associated Proteins,Membrane Protein, Cell,Membrane Protein, Integral,Membrane Proteins, Integral,Protein, Cell Membrane,Protein, Cell Surface,Protein, Integral Membrane,Protein, Membrane,Protein, Membrane-Associated,Protein, Surface,Proteins, Cell Membrane,Proteins, Cell Surface,Proteins, Integral Membrane,Proteins, Membrane,Proteins, Membrane-Associated,Proteins, Surface,Surface Protein, Cell
D011296 Prenatal Diagnosis Determination of the nature of a pathological condition or disease in the postimplantation EMBRYO; FETUS; or pregnant female before birth. Diagnosis, Prenatal,Fetal Diagnosis,Fetal Imaging,Fetal Screening,Intrauterine Diagnosis,Antenatal Diagnosis,Antenatal Screening,Diagnosis, Antenatal,Diagnosis, Intrauterine,Prenatal Screening,Antenatal Diagnoses,Antenatal Screenings,Diagnosis, Fetal,Fetal Diagnoses,Fetal Imagings,Fetal Screenings,Imaging, Fetal,Intrauterine Diagnoses,Prenatal Diagnoses,Prenatal Screenings,Screening, Antenatal,Screening, Fetal,Screening, Prenatal
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D005260 Female Females
D006580 Genetic Carrier Screening Identification of individuals who are heterozygous at a GENETIC LOCUS for a recessive PHENOTYPE. Carriers, Genetic, Detection,Genetic Carriers, Detection,Heterozygote Detection,Carrier Detection, Genetic,Detection, Genetic Carrier,Genetic Carrier Detection,Heterozygote Screening,Carrier Screening, Genetic,Detection, Heterozygote,Screening, Genetic Carrier,Screening, Heterozygote,Screenings, Genetic Carrier
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000465 Algorithms A procedure consisting of a sequence of algebraic formulas and/or logical steps to calculate or determine a given task. Algorithm
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity

Related Publications

G Pescia, and G Van Melle, and F Thonney, and C Auer, and D Schorderet, and S Fokstuen
[Screening for mucoviscidosis].
September 1976, Monatsschrift fur Kinderheilkunde,
G Pescia, and G Van Melle, and F Thonney, and C Auer, and D Schorderet, and S Fokstuen
[Screening for mucoviscidosis (cystic fibrosis-CF). Systematic review and results].
December 1971, Monatsschrift fur Kinderheilkunde,
G Pescia, and G Van Melle, and F Thonney, and C Auer, and D Schorderet, and S Fokstuen
[Mucoviscidosis: France is heading towards biological rather than genetic screening].
November 2005, Revue medicale suisse,
G Pescia, and G Van Melle, and F Thonney, and C Auer, and D Schorderet, and S Fokstuen
[Screening of newborn infants for mucoviscidosis].
December 1979, Orvosi hetilap,
G Pescia, and G Van Melle, and F Thonney, and C Auer, and D Schorderet, and S Fokstuen
[Neonatal screening of mucoviscidosis].
January 1987, Archives francaises de pediatrie,
G Pescia, and G Van Melle, and F Thonney, and C Auer, and D Schorderet, and S Fokstuen
Towards a systematic nationwide screening strategy for MODY.
April 2017, Diabetologia,
G Pescia, and G Van Melle, and F Thonney, and C Auer, and D Schorderet, and S Fokstuen
[THE IMPRINT TEST IN SCREENING FOR MUCOVISCIDOSIS].
January 1965, Ceskoslovenska pediatrie,
G Pescia, and G Van Melle, and F Thonney, and C Auer, and D Schorderet, and S Fokstuen
[Systematic neonatal screening for mucoviscidosis using an immunoreactive trypsin blood assay. Evaluation of 80,000 tests].
April 1983, Archives francaises de pediatrie,
G Pescia, and G Van Melle, and F Thonney, and C Auer, and D Schorderet, and S Fokstuen
[Mucoviscidosis screening with immunoreactive trypsin].
January 1992, Wiener klinische Wochenschrift,
G Pescia, and G Van Melle, and F Thonney, and C Auer, and D Schorderet, and S Fokstuen
[Screening for mucoviscidosis by meconium analysis. 7 years' experience].
March 1981, Journal de genetique humaine,
Copied contents to your clipboard!